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Abstract: Two 1-year studies evaluated the long-term efficacy and safety of tiotropium 5 or 10 µg 
versus placebo, inhaled via the Respimat® Soft MistTM Inhaler (SMI). The two studies were com-
bined and had 4 co-primary endpoints (trough FEV1 response, Mahler Transition Dyspnea Index 
[TDI] and St George’s Respiratory Questionnaire scores all at week 48, and COPD exacerbations 
per patient-year). A total of 1990 patients with COPD participated (mean FEV1: 1.09 L). The mean 
trough FEV1 response of tiotropium 5 or 10 µg relative to placebo was 127 or 150 mL, respectively 
(both P  0.0001). The COPD exacerbation rate was significantly lower with tiotropium 5 µg 
(RR = 0.78; P = 0.002) and tiotropium 10 µg (RR = 0.73; P = 0.0008); the health-related quality 
of life and Mahler TDI co-primary endpoints were significantly improved with both doses (both 
P  0.0001). Adverse events were generally balanced except anticholinergic class effects, which 
were more frequent with active treatment. Fatal events occurred in 2.4% (5 µg), 2.7% (10 µg), 
and 1.6% (placebo) of patients; these differences were not significant. Tiotropium Respimat® 
SMI 5 µg demonstrated sustained improvements in patients with COPD relative to placebo and 
similar to the 10 µg dose but with a lower frequency of anticholinergic adverse events.
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Introduction
Tiotropium, a long-acting anticholinergic used to treat chronic obstructive pulmonary 
disease (COPD), can be delivered via the Respimat® Soft MistTM Inhaler (SMI), which 
uses mechanical energy (a spring) to generate a fine, slow-moving mist from an aqueous 
solution. The Respimat® SMI has a number of benefits; from the patient’s perspective, 
Respimat® SMI is a multi-dose device, simple to coordinate, and the delivered dose 
is independent of inspiratory effort. In terms of access to the airways, 62% of the 
delivered dose contains particles that are 5.8 µm, which means that this fraction is 
approximately 2.5 times higher than for most metered-dose inhalers (MDIs),1,2 and 
the mean velocity of the Soft MistTM is approximately 5 times lower.3,4 Both of these 
factors contribute to a reduction in oropharyngeal deposition and to an increase in 
lung deposition.1,2 Dose-ranging studies have confirmed that a low dose of tiotropium 
(5 and 10 µg) is needed in the Respimat® SMI.5,6
The objectives of the current studies were to evaluate the long-term efficacy 
and safety of two doses of once-daily tiotropium versus placebo, delivered via the 
Respimat® SMI. Two studies identical in design were performed based on Food and 
Drug Administration (FDA) requirements; however, the endpoints were combined to 
provide the best estimation of the differences for the four co-primary endpoints and 
to provide adequate statistical power for COPD exacerbations.
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Allowed study medication
Oral (up to 10 mg daily of prednisone) and inhaled 
  corticosteroids, theophylline preparations, mucolytic 
agents and antileukotrienes were allowed if stabilized for 
at least 6 weeks prior to and during the study. Patients on 
long-acting β-adrenergics and inhaled corticosteroids were 
switched to a monoproduct inhaled corticosteroid prior to 
run-in. Salbutamol MDI was used as rescue medication. 
A locally available commercial brand of salbutamol MDI 
was purchased by the Boehringer Ingelheim affiliate and 
provided to the investigator sites.
Efficacy endpoints
There were 4 co-primary endpoints for both studies:
•  The trough FEV1 response at week 48 (24-hour post-
dose FEV1 expressed as change from study baseline 
predose FEV1)
•  St George’s Respiratory Questionnaire (SGRQ) total 
score at the end of the 48-week treatment period
•  The Mahler Transition Dyspnea Index (TDI) focal score 
after 48 weeks of treatment
•  COPD exacerbations per patient-year defined as respira-
tory adverse events lasting 3 days and requiring treat-
ment with antibiotics and/or oral corticosteroids and/or 
a significant change in prescribed respiratory medication 
including inhaled bronchodilators.
This definition of an exacerbation is consistent with 
previously published trials8 in order to permit comparisons 
with previous studies. The exacerbation endpoints in the 
study included:
•  The patients (%) with at least 1 COPD exacerbation
•  The number of exacerbations per patient-year of treatment
•  The time to first COPD exacerbation.
The total time in exacerbations is the number of days, as 
determined by the physician (based on clinical judgment) 
that exacerbations continued, expressed as a percentage of 
the total time that each patient remained on treatment.
Secondary endpoints included FVC, peak expiratory flow 
rate (PEFR) (measured using a mechanical meter) and weekly 
mean number of occasions (per day as needed) that rescue 
medication was used. COPD symptom scores (wheezing, 
shortness of breath, coughing, and tightness of chest) were 
based on the investigator’s assessment of the patient’s condition 
during the week just prior to the clinic visit. The Physician’s 
Global Evaluation (PGE), which was based on the physician’s 
opinion of the patient’s overall clinical condition, and was rated 
from poor (1−2) to excellent (7−8), and the Patient’s Global 
Rating (PGR), which was performed by the patients who rated 
Methods
Population
Males and females aged 40 years with a diagnosis of 
COPD7 and stable, moderate-to-severe airway obstruction 
(prebronchodilator forced expiratory volume in 1 second 
[FEV1]  60% predicted and FEV1  70% of forced vital 
capacity [FVC]), and with a smoking history of 10 pack 
years were included. We used the criteria of the American 
Thoracic Society7 for the definition of moderate-to-severe 
COPD to facilitate outcome comparisons with the previously 
reported 1-year tiotropium HandiHaler® data. Patients with a 
confounding disease, including other significant respiratory 
conditions, were excluded, as were those who had a disease 
that might put them at risk because of study participation. 
Other exclusion criteria included known hypersensitivity 
to anticholinergics or any component of the Respimat® 
inhalation solution; drugs contraindicated with anticholin-
ergics; prior use of Spiriva® HandiHaler®; regular use of 
daytime oxygen therapy, oral β-adrenergics, or long-acting 
β-adrenergics; or significant alcohol or drug abuse. All 
patients provided written, informed consent to participate. 
The protocol was approved by institutional ethics review 
boards of participating centers.
Study design
Two identical, 1-year, multicenter, multinational, randomized, 
double-blind, parallel-group studies (#205.254 [NCT00168844] 
and #205.255 [NCT00168831]) were performed comparing 
orally inhaled tiotropium 5 and 10 µg with placebo in patients 
with COPD. This paper reports the combined analyses (per 
protocol), and also highlights any significant differences 
between the individual studies.
Following an initial screening visit and 2-week run-in 
phase, eligible patients were randomized to receive tiotropium 
Respimat® SMI 5 µg (2 actuations of 2.5 µg tiotropium [Tio 
R5]), tiotropium Respimat® SMI 10 µg (2 actuations of 5 µg 
tiotropium [Tio R10]), or Respimat® placebo (2 actuations 
of placebo inhalation solution) once daily in the morning 
for 48 weeks. All drugs were supplied by Boehringer Ingel-
heim, Ingelheim am Rhein, Germany. Recruitment for the 
studies took place from January 2003 to December 2005. 
An additional retrospective study (#205.392) was conducted 
from March 2007 to January 2008 to capture data from all 
prematurely discontinued patients for the intended treatment 
period of 48 weeks to 30-day follow-up, including vital status 
information and changes in treatment after discontinuation 
of trial medication.International Journal of COPD 2010:5 199
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their condition as “much better” to “much worse”, were also 
assessed. Detailed information on exacerbations and COPD 
exacerbation-related hospitalizations were recorded.
Clinical efficacy measures, including spirometry and 
health-related quality-of-life (HRQoL), patient diary cards 
information (predose and evening PEFR, occasions of rescue 
medication use, and drug compliance, ie, whether treatment 
was taken or not) were measured throughout the 48-week 
treatment period. Some variables (diary cards, SGRQ, Mahler 
TDI, COPD symptom scores, PGE, PGR, and adverse events) 
were also measured 21 days after medication had stopped; this 
was defined in the protocol. Data collected during the 21-day 
follow-up period were used descriptively to evaluate any evi-
dence of a rebound effect when tiotropium was stopped.
Safety endpoints
Adverse and fatal adverse events were monitored throughout 
the run-in, 48-week treatment period and for a 30-day follow-
up. End-of-study (week 48) changes in vital signs, routine 
laboratory, and physical examination were also recorded. As 
benzalconium chloride and ethylene diamine tetra-acetic acid 
are excipients in the Respimat® SMI formulation that have 
been reported to cause dose-related bronchoconstriction,9–11 
particular attention was paid to respiratory events indicative 
of paradoxical bronchoconstriction, such as a drop in FEV1 
15% from study day baseline, rescue medication use, 
cough, wheeze, and dyspnea within 30 minutes after treat-
ment administration. Cardiovascular safety was monitored in 
a subset of patients using 12-lead electrocardiogram (ECG) 
and Holter monitoring; these measures were performed at 
randomization, week 16, and week 40. The retrospective 
study also collected vital status information for patients 
who discontinued prematurely, covering the mean treatment 
period plus observation period (ie, a total of 369 days).
Statistical analysis
Each study was sufficiently powered to detect differences in 
three co-primary endpoints (trough FEV1 response, SGRQ 
total score, and Mahler TDI focal score), but were not suf-
ficiently powered individually to test for between-treatment 
group differences in exacerbations. This was described in 
the protocols and was prespecified and FDA-approved that 
the studies would be combined. In both individual studies, 
a sample of 810 patients was considered adequate to detect 
a difference of 0.13 L in mean trough FEV1 (5% significance 
level), and the combined analysis had at least 95% power to 
detect a difference of 0.05 L in mean trough FEV1 response 
(5% significance level). The combined analysis was adequate 
to detect a mean difference of 0.4 exacerbations per year with 
76% power (5% significance level), to detect a mean differ-
ence in Mahler TDI focal score of 1 unit with 90% power 
and to detect a mean difference of 4 units in the SGRQ total 
score with 96% power (5% significance level).
Three of the co-primary endpoints (trough FEV1 response, 
SGRQ total score, and Mahler TDI focal score at 48 weeks) 
were analyzed using fixed effects analysis of covariance 
(ANCOVA) with terms for smoking status at study entry, 
center and treatment group with baseline value as a continuous 
covariate. Incorporating center as a fixed effect was considered 
a more conservative approach and was also prespecified in 
the analysis plan prior to unblinding. Fisher’s least significant 
difference procedure was applied where pair-wise com-
parisons between treatment groups were made. Responders 
were defined as those achieving a change of 4 units in the 
SGRQ total score and 1 unit in the Mahler TDI focal score 
(minimal clinically important differences [MCID]).12–14 The 
remaining co-primary endpoint, COPD exacerbations, was 
evaluated using Wilcoxon–Mann–Whitney tests for pair-wise 
comparisons. Kaplan–Meier estimates of the probability of 
no COPD exacerbation on any given test day were performed. 
The analysis of COPD exacerbation was performed using a 
pooled analysis, and as both studies were similar in design and 
execution, each trial was not incorporated as a random effect 
in the model. Pair-wise treatment comparisons of the time to 
the first COPD exacerbation were made using the log-rank 
test. Similar analyses were performed for hospitalizations.
An ANCOVA  model  was  also  used  to  analyze 
the secondary efficacy variables (FVC, PGE, COPD symp-
tom scores, PEFR, and rescue medication). An analysis of 
variance model, which included terms for smoking status at 
study entry, center and treatment group, was performed on 
the PGR data. Only those patients with baseline and on-treat-
ment data for at least one primary endpoint were included in 
the efficacy analyses. Randomized patients who received 1 
dose of study medication were included in the safety analy-
sis. Post-hoc subgroup analyses were performed on trough 
FEV1 response at 48 weeks to see whether patients who were 
taking inhaled corticosteroids at inclusion responded differ-
ently to those patients not taking inhaled corticosteroids. 
The model used to analyze the co-primary endpoint trough 
FEV1 response at 48 weeks was also used for this subgroup 
analysis.
Descriptive statistics were used for safety outcomes; 
safety was not a predefined endpoint so the trials were not 
powered to detect differences in incidence of adverse events 
between treatment groups.International Journal of COPD 2010:5 200
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Results
Patient disposition and characteristics
A combined total of 2544 patients signed informed consent 
and were screened for entry; however, 554 did not meet the 
inclusion criteria. A total of 1990 patients were randomized 
and received treatment; 93 patients were excluded from the 
FEV1 assessments; 192 patients were excluded from the 
SGRQ and Mahler TDI assessments and 90 patients were 
excluded from rescue medication and PEFR assessments. 
The main reasons for these exclusions were data not evalu-
able or patients having received less than 5 days of study 
treatment. The baseline characteristics were comparable 
between randomized treatment groups (Table 1). Adherence 
to medication was high; 96.1% (Tio R5), 95.4% (Tio R10), 
and 95.7% (placebo) took medication as prescribed during 
the study. More patients in the placebo groups discontinued 
treatment prematurely compared with the two tiotropium 
treatment groups (Table 2). The discontinued patients had 
more severe lung disease at baseline than completers, 
and this difference was more pronounced in the placebo 
groups. Tiotropium-treated patients completing the studies 
therefore had slightly worse lung function at baseline than 
placebo-treated patients who completed the study (differ-
ence in mean, placebo–Tio R5: FEV1 = 0.028 L [standard 
error of the mean [SEM] = 0.024 L] and placebo–Tio R10: 
FEV1 = 0.026 L [SEM = 0.025 L]).
Spirometry assessments
Long-term (24-hour) bronchodilation was achieved after 
treatment with once-daily Tio R5 and Tio R10 (Figure 1a). 
The mean (SEM) differences between Tio R5 and Tio R10 
and placebo for the first co-primary endpoint, combined 
mean trough FEV1 response, was 127 mL and 150 mL, 
respectively (both P  0.0001) (Table 3a). There was also 
a slight, nonsignificant improvement in combined mean 
(SEM) trough FEV1 of 23 mL after treatment with Tio 
R10 compared with Tio R5 (Figure 1a) (Table 3a). There 
was no evidence of tachyphylaxis as the improvements in 
FEV1 after active treatments on day 1 were comparable with 
those observed after 48 weeks (Figure 1a). FEV1 revers-
ibility at baseline did not influence responsiveness to Tio 
R5 and Tio R10 measured as post-dose FEV1 on Test Day 
337 (Table 3b). Patients treated with placebo, on the other 
hand, appeared to have a marked decrease in reversibility 
response after 48 weeks.
There was also a substantial increase in trough FVC 
on active treatment (difference in mean, Tio R5–placebo: 
0.209 L [SEM = 0.027 L] and Tio R10–placebo: 0.286 L 
Table 1 Patient demographics and characteristics of all randomized patients
Variables*  Tiotropium Respimat®  
SMI 5 µg (n = 670)
Tiotropium Respimat®  
SMI 10 µg (n = 667)
Placebo  
(n = 653)
Male:female (%) 73.3:26.7 74.7:25.3 74.6:25.4
Age (years) 64.7 (8.6) 65.1 (8.5) 65.2 (8.7)
Current smoker (%) 37.9 34.8 36.1
Duration of COPD (years) 8.3 (6.4) 9.0 (7.4) 9.5 (7.5)
FEV1 (L) 1.066 (0.4) 1.065 (0.40) 1.058 (0.4)
Pre-bronchodilator FEV1 (% predicted normal) 38.0 (11.7) 37.7 (11.7) 37.5 (11.6)
Post-bronchodilator FEV1 (% predicted normal) 46.6 45.3 46.2
FEV1/FVC (%) 42.4 (11.5) 42.4 (11.1) 42.1 (11.0)
FEV1 (% reversibility at 30 minutes following  
400 µg salbutamol)†
20 (18) 19 (17) 21 (17)
Patients taking any pulmonary medication (%) 80 86 85
Corticosteroids, oral (%) 3 3 3
Corticosteroids, inhaled (%) 49 57 55
β-adrenergics, short-acting (%) 52 57 53
β-adrenergics, long-acting (%) 30 30 29
Anticholinergics, short-acting (%) 45 44 45
Xanthines (%) 14 16 15
Mucolytics (%) 4 3 4
Notes: *Mean (SD) unless otherwise stated; †Mean (median) compared with baseline values. Predicted normals from European Community for Steel and Coal Statement.15
Abbreviations: COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in one second; FVC, forced vital capacity; SMI, Soft MistTM Inhaler.International Journal of COPD 2010:5 201
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[SEM = 0.027 L]; both P  0.0001), which was generally 
sustained over the 48-week period (Figure 1b). Morning 
and evening PEFR were also statistically significantly 
(P  0.0001) improved after treatment with both doses of 
tiotropium compared with placebo (Table 3a).
Lung function data according to whether patients used 
inhaled corticosteroids or not at inclusion is shown in 
Table 4. Numerically, the patients who were not on inhaled 
corticosteroids had a slightly better lung function than those 
patients who were using inhaled corticosteroids. However, 
  irrespective of whether the patients were on inhaled corti-
costeroids or not, both groups and both tiotropium doses 
showed statistically significant (P  0.0001) improvements 
compared to placebo for trough FEV1, AUC(0–3 h) FEV1, and 
peak FEV1. The magnitude of the changes in pulmonary 
function indices for the active treatments compared with 
placebo were on average slightly smaller for the patients 
who were not on inhaled corticosteroids compared with 
those who were.
HRQoL assessments
The improvement in the unadjusted second co-primary 
endpoint, SGRQ total score, for both tiotropium doses was 
statistically superior to placebo (–3.5 [Tio R5−placebo] and 
–3.8 [Tio R10−placebo]; P  0.0001) (Table 3a), and the 
adjusted mean change from baseline to week 48 exceeded 
the accepted MCID of 4 units in the SGRQ after active 
treatment in both studies: Tio R5: –5.1 units; Tio R10: 
–5.5 units; placebo: –1.6 units. The percentage of patients 
with improvements exceeding the MCID (ie, responders) at 
week 48 was also statistically significantly higher (P  0.05) 
for Tio R5 (50.5%) and Tio R10 (51.4%) compared with 
placebo (40.7%).
Dyspnea scores
For the Mahler TDI focal score, a third co-primary endpoint, 
both tiotropium doses were statistically superior (P  0.0001) 
to placebo at week 48, and the difference exceeded the quoted 
MCID of 1 unit (Table 3a). The percentage of responders 
(meeting or exceeding MCID) at week 48 was significantly 
higher (P  0.0001) for both tiotropium groups compared 
with placebo (Tio R5 56%, Tio R10 56% vs placebo 44%).
COPD exacerbations and hospitalizations
Improvements in favor of tiotropium were also seen in the 
fourth co-primary efficacy endpoint of COPD exacerbations 
(Table 5). The mean COPD exacerbation rate (per patient-
year) was statistically significantly reduced on treatment with 
both tiotropium doses and in each of the trials; the odds ratio 
was 0.75 (Tio R5 vs placebo; P  0.01) and 0.74 (Tio R10 
vs placebo; P  0.001) (Table 5). The time (lower quartile) 
to first exacerbation (days) was not statistically significant 
for the Tio R5 dose compared with placebo in trial #205.254 
(P = 0.09), but when the results of both trials were combined, 
results were statistically significant for both tiotropium doses 
(P  0.0001). The probability of remaining exacerbation-free 
over the 48-week treatment period was also higher in both 
tiotropium groups compared with placebo (Figure 2). The 
secondary exacerbation measures were all statistically 
significantly improved after active treatments compared 
with placebo (Table 5). Only a small percentage of patients 
experienced 1 COPD exacerbation-related hospitalization, 
which was lower in both tiotropium groups compared with 
placebo, but not statistically significant.
Both tiotropium doses significantly improved all four 
  co-primary endpoints in the combined analysis. Also for each 
of the separate trials, the improvements were comparable 
Table 2 Disposition and spirometry at baseline in accordance with discontinuation status
Variables (mean ± SEM unless  
otherwise stated)
Tiotropium Respimat®  
SMI 5 µg (n = 670)
Tiotropium Respimat®  
SMI 10 µg (n = 667)
Placebo  
(n = 653)
Completed patients (%) 82.8 79.6 68.6
Adverse events (%) 10 11.8 18.7
Worsening of disease under study (%) 4.6 5.1 14.1
FEV1, all patients (L) (% predicted normal) 1.066 ± 0.015 [38.0] 1.065 ± 0.016 [37.7] 1.058 ± 0.015 [37.5]
FEV1, completed patients (L) (% predicted normal) 1.081 ± 0.016* [38.2] 1.082 ± 0.017* [38.0] 1.108 ± 0.018 [39.1]
FEV1, discontinued patients (L) (% predicted normal) 1.001 ± 0.042 [36.9] 1.000 ± 0.039 [36.4] 0.950 ± 0.028 [34.1]
Difference in FEV1, completed minus discontinued 
patients (L)†
0.079 ± 0.040  0.082 ± 0.039  0.158 ± 0.032 
Notes: *P  0.0001; mean difference between active treatment and placebo for day 337. †Represents the mean (SEM) difference in baseline FEV1 values (by treatment group) 
between patients who completed the study and patients who discontinued prematurely.
Abbreviations: FEV1, forced expiratory volume in 1 second; SMI, Soft MistTM Inhaler.International Journal of COPD 2010:5 202
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Figure 1 The adjusted mean (SEM) trough (a) FEV1 (L) response and (b) FVC (L) response during 48 weeks of treatment with tiotropium 5 µg, tiotropium 10 µg, or placebo 
(n = 1897) (P  0.0001 for tiotropium 5 µg−placebo and tiotropium 10 µg−placebo for mean improvement in FEV1 and FVC).
Abbreviations: FEV1 , forced expiratory volume in 1 second; FVC, forced vital capacity; SMI, Soft MistTM Inhaler.
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between the two tiotropium doses, and were significant for 
both doses (individual data not shown).
Additional secondary outcomes
Over the 1-year period, active treatment was associated 
with, on average, a reduction of five occasions per week in 
rescue medication use, compared with placebo (P  0.0001) 
(Table 3a). Mean PGE, PGR, and COPD symptom scores 
at week 48 were also statistically significantly improved 
(P  0.0001 [P  0.05 for coughing]) compared with 
placebo. A total of 1524 (76.6%) of the 1990 patients ran-
domized to treatment completed the planned observation 
time. The post-treatment (ie, day 21) SGRQ total scores 
were –4.0 (Tio R5), –4.0 (Tio R10), and –3.5 (placebo); the 
post-treatment Mahler TDI focal scores were 1.0 (Tio R5), 
1.3 (Tio R10), and 1.5 (placebo); the post-treatment PGR International Journal of COPD 2010:5 203
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Table 3 (A) The mean (SEM) treatment differences at week 48 for primary and secondary efficacy variables and (B) the difference 
between post-bronchodilator FEV1 at baseline and post-dose on test day 337
(A) Treatment differences 
 
 Treatment† comparison    
Tiotropium Respimat®  
SMI 5 µg–placebo
Tiotropium Respimat®  
SMI 10 µg–placebo
Tiotropium Respimat®   
SMI 10 µg–5 µg
Primary
Trough (24-h post-dose) FEV1 (L) response  
(n = 1897)
0.127* (0.013) 0.150* (0.013) 0.023 (0.013)
[95% CI] [0.101, 0.153] [0.124, 0.175] [–0.002, 0.048]
SGRQ total score (n = 1798) –3.5* (0.7) –3.8* (0.7) –0.4 (0.7)
[95% CI] [–4.9, –2.1] [–5.3, –2.4] [–1.7, 1.0]
Mahler TDI focal score (n = 1798) 1.05* (0.17) 1.08* (0.17) 0.02 (0.16)
[95% CI] [0.73, 1.38] [0.75, 1.40] [–0.29, 0.34]
Secondary
‡Rescue medication use (occasions per day) 
[n = 1900]
–0.6* (0.1) –0.7* (0.1) –0.1 (0.1)
[95% CI] [−0.8, −0.4] [−0.9, −0.5] [−0.3, 0.1]
‡Morning PEFR (L/min) (n = 1900) 22* (3) 28* (3) 5 (3)
[95% CI] [17, 28] [22, 33] [0, 10]
‡Evening PEFR (L/min) (n = 1900) 27* (3) 33* (3) 6** (3)
[95% CI] [22, 32] [28, 39] [1, 12]
(B) Treatment comparison Tiotropium Respimat®  
SMI 5 µg
Tiotropium Respimat®  
SMI 10 µg
Placebo
Post-bronchodilator FEV1 at baseline 1.281 1.281 1.282
Post-bronchodilator FEV1 on test day 337 
(30 minutes post-dose)
1.242  1.270  1.053 
*P  0.0001 vs placebo; **P  0.05.
Notes: †Adjusted for smoking status at entry, center and baseline value.   A last observation carried forward approach was used for all missing data except rescue medication 
use and PEFR. ‡These data reflect the overall mean.
Abbreviations: FEV1, forced expiratory volume in 1 second; PEFR, peak expiratory flow rate; SGRQ, St George’s Respiratory Questionnaire; TDI, Transition Dyspnea Index; 
SMI, Soft MistTM Inhaler.
scores were 3.3 (Tio R5), 3.2 (Tio R10), and 3.2 (placebo); the 
post-treatment PGE scores were 0.4 (Tio R5), 0.4 (Tio R10), 
and 0.5 (placebo). There was no evidence of a rebound effect 
in the COPD symptom scores.
Safety assessments
The mean exposure to treatment was higher in both tiotro-
pium groups compared with placebo, mainly because fewer 
patients discontinued prematurely due to worsening of disease 
under study (Table 2). Both tiotropium groups were associ-
ated with a higher incidence of gastrointestinal disorders 
than placebo, which was primarily due to dry mouth (Tio R5: 
7.2%; Tio R10: 14.5%; placebo: 2.1%) and constipation 
(Tio R5: 2.1%; Tio R10: 2.2%; placebo: 1.5%). In addition, 
urinary tract infections were higher in the tiotropium groups 
(Tio R5: 2.5%; Tio R10: 4.2%; placebo: 1.1%).
A total of 17.2% of patients experienced at least one 
serious adverse event, and these were generally balanced 
across the treatment groups (Table 6). COPD exacerbations 
were the most commonly reported serious adverse event 
(Tio R5: 4.9%; Tio R10: 6.0%; placebo: 5.7%). Cardiac 
angina was more common on active treatments than placebo 
(Tio R5: 0.4%; Tio R10: 1.0%; placebo: 0.2%), whereas 
myocardial infarction was more frequent in the placebo group 
(Tio R5: 0.3%; Tio R10: 0.1%; placebo: 0.9%). There were 
no clinically relevant changes in ECG or Holter monitoring 
parameters for all treatment groups. Paradoxical bronchocon-
striction was not observed for any treatment. The incidence of 
respiratory events, rescue medication use, and asymptomatic 
decreases in FEV1 within 30 minutes of treatment adminis-
tration were small and remained unchanged throughout the 
study across all treatment groups.
The occurrence of fatal adverse events during treatment 
plus the 30-day follow-up observation period was lower in 
the placebo group than active treatments. When the results 
from patients who discontinued treatment prematurely were International Journal of COPD 2010:5 204
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Table 4 A comparison of lung function parameters according to whether patients used ICS at baseline
Treatment Tiotropium Respimat® SMI 5 µg Tiotropium Respimat® SMI 10 µg Placebo
ICS use at baseline Yes No Yes No Yes No
Patients (n) 316 334 366 278 327 276
Mean (SD) FEV1 36.9 39.0 37.1 38.5 36.9 38.6
(% predicted normal) at baseline (11.7) (11.5) (12.0) (11.4) (11.1) (11.2)
Mean (SD) 41.8 43.0 42.2 42.7 41.5 43.1
FEV1/FVC at baseline (11.8) (11.2) (10.6) (11.8) (10.7) (11.1)
Mean (SEM) 0.130 0.108 0.163 0.135 – –
∆trough FEV1 (L) (0.018) (0.020) (0.017) (0.021) – –
vs placebo at day 337 P  0.0001 P  0.0001 P  0.0001 P  0.0001 – –
Mean (SEM) 0.202 0.192 0.231 0.216 – –
∆FEV1 (L) AUC(0–3 h) vs (0.019) (0.021) (0.018) (0.022) – –
placebo at day 337 P  0.0001 P  0.0001 P  0.0001 P  0.0001 – –
Mean (SEM) 0.211 0.197 0.238 0.222 – –
∆Peak FEV1 (L) (0.020) (0.023) (0.020) (0.024) – –
vs placebo at day 337 P  0.0001 P  0.0001 P  0.0001 P  0.0001 – –
Abbreviations: ICS, inhaled corticosteroid; ∆, difference; AUC, area under the curve; FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; SMI, Soft MistTM 
Inhaler.
included (ie, information of an additional 409 patients, 
covering 97.7% of the 1990 randomized patients), this 
difference was reduced to a nonsignificant numerical 
imbalance between active treatment groups and placebo 
(Table 6).
Discussion
The data show that once-daily tiotropium (5 and 10 µg) Respi-
mat® SMI provides sustained (ie, 24-hour) bronchodilation, 
and the spirometry improvements achieved (ie, trough FEV1 
response and trough FVC supported by changes in morning 
and evening PEFR) were sustained over 48 weeks, without 
evidence of tachyphylaxis. These improvements are consis-
tent with studies using HandiHaler®.6,16–22 In our analysis, 
which included patients with a mean baseline FEV1 of 1.06 
L, the mean trough FEV1 improved by 127 and 150 mL on 
Tio R5 and Tio R10, respectively. A previous 12-month study 
in which 550 patients with a mean baseline FEV1 of 1.04 L 
(39.1% predicted normal) were randomized to treatment with 
tiotropium 18 µg HandiHaler® showed that the mean trough 
FEV1 was elevated 110 mL over baseline.19
In our analysis, tiotropium (both doses) also improved the 
HRQoL and dyspnea measures, and there was no evidence of 
a post-treatment rebound effect during the 21-day follow-up 
period. The SGRQ total score was –3.5 (Tio R5–placebo) and 
–3.8 (Tio R10–placebo) and the Mahler TDI focal score 1 unit.   
Table 5 COPD exacerbation and related hospitalizations in patients treated with tiotropium 5 µg, 10 µg, or placebo
   Tiotropium Respimat®  
SMI 5 µg (n = 670)
Tiotropium Respimat®  
SMI 10 µg (n = 667)
Placebo  
(n = 653)
Patients (%) with 1 exacerbation 37.2* 36.9* 44.1
Odds ratio† [95% CI] 0.75* [0.60, 0.93] 0.74** [0.59, 0.92] 1.00
Time (lower quartile) to first exacerbation (days) 160** 178** 86
COPD exacerbation rate (per patient year) 0.93 1.02 1.91
Mean time (%) in exacerbation§ 4.0* 3.9* 5.6
Mean hospitalization‡ per patient-year 0.12 0.16 0.20
Patients (%) with 1 hospitalization‡ 5.8 5.8 6.7
Notes: †Versus placebo (Chi2, ie, unadjusted for extent of exposure); ‡Due to COPD exacerbation; §Expressed as the mean of the percentage of days each patient remained 
on randomized treatment. *P  0.01; **P  0.001 vs placebo.
Abbreviations: COPD, chronic obstructive pulmonary disease; SMI, Soft MistTM Inhaler.International Journal of COPD 2010:5 205
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In a previous study involving 1207 patients, the SGRQ 
total score and Mahler TDI focal score improved by 4.2 and 
1.1 units, respectively, following 6 months of treatment with 
tiotropium 18 µg HandiHaler®.20
The COPD exacerbation rate (per patient-year) was 
significantly lower after treatment with either dose of tiotro-
pium (37.2% in the Tio R5 group and 36.9% in the Tio 
R10 group experienced 1 exacerbation during the year).   
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Figure 2 Kaplan–Meier plot illustrating probability of remaining exacerbation-free over the 48-week treatment period (N = 1990) (P  0.0001 for tiotropium 5 µg−placebo 
and tiotropium 10 µg−placebo for mean time [lower quartile] to first exacerbation).
Abbreviations: COPD, chronic obstructive pulmonary disease; SMI, Soft MistTM Inhaler.
Table 6 The frequency (n [%]) of patients with 3% adverse events in any treatment group and mortality data
   Tiotropium Respimat®  
SMI 5 µg (n = 670)
Tiotropium Respimat®  
SMI 10 µg (n = 667)
Placebo  
(n = 653)
Patients with any adverse event 505 (75.4) 525 (78.7) 502 (76.9)
With serious adverse events 108 (16.1) 125 (18.7) 110 (16.8)
Mean exposure to treatment (days) 304.7 297.2 265.6
Gastrointestinal disorders 142 (21.2) 193 (28.9) 97 (14.9)
General disorders and administration site conditions 54 (8.1) 33 (4.9) 39 (6.0)
Infections and infestations 90 (13.4) 95 (14.2) 79 (12.1)
Musculoskeletal and connective tissues disorders 94 (14.0) 100 (15.0) 78 (11.9)
Nervous system disorders 75 (11.2) 65 (9.7) 66 (10.1)
Lower respiratory system disorders 304 (45.4) 299 (44.8) 360 (55.1)
Upper respiratory system disorders 208 (31.0) 203 (30.4) 171 (26.2)
Vascular disorders 30 (4.5) 41 (6.1) 35 (5.4)
All-cause mortality on treatment plus 30-day observation 
period†
12 (1.79) 17 (2.55)* 5 (0.77)
All-cause mortality including discontinued patients‡ 16 (2.39) 18 (2.70) 10 (1.53)
*P = 0.0161 vs placebo. †All fatal adverse events reported until day 369; this reflects the mean exposure to treatment for study completers plus the 30-day observation period. 
However, four known fatal events were excluded from this analysis: 2 cases in the placebo group had unknown outcomes and 1 case in each of the active treatment groups as 
the patients died more than 366 days after their first dose of medication. ‡This also includes the retrospective study 205.392.
Notes: Classified using Medical Dictionary for Regulatory Activities (MedDRA Version 8) system organ class.
Abbreviations: SMI, Soft MistTM Inhaler.International Journal of COPD 2010:5 206
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These findings are generally consistent with those observed 
with tiotropium 18 µg HandiHaler®,8, 21 in which, over 
6 months, the percentage of patients experiencing 1 exac-
erbation was 27.9% compared with 32.3% in the placebo 
group.8 In the present trial, however, the exacerbation rate 
in the placebo group was much higher (44.1%) than in the 
HandiHaler® trials. Rescue medication use was significantly 
lower in the tiotropium groups compared with placebo dur-
ing the 48-week study, which indicates that the patients were 
better controlled using once-daily tiotropium.
Adverse events and serious adverse events were generally 
well balanced between active treatment groups, and were 
generally comparable with those observed with tiotropium 
18 µg HandiHaler®. The higher incidence of urinary tract 
infections and dry mouth in the tiotropium groups is a known 
class effect of anticholinergics. In our analysis, the incidence 
of dry mouth was numerically lower in the tiotropium 5 µg 
group compared with tiotropium 10 µg (7.2% vs 14.5%, 
respectively). In a previously reported study in 207 COPD 
patients, there was a similar systemic exposure between 
tiotropium 5 µg (via Respimat® SMI) and tiotropium 18 µg 
(HandiHaler®) whereas the 10 µg dose (Respimat® SMI) had 
almost double the systemic exposure.6 In the current study, 
there was no evidence of paradoxical (administration-related) 
bronchoconstriction, which is consistent with previous 
published findings.23–25 Cardiac angina was more common 
on active treatments than placebo (Tio R5: 0.4%; Tio R10: 
1.0%; placebo: 0.2%). The reason for this difference is not 
apparent, but it could be speculated that, in patients with silent 
or undiagnosed ischemic heart disease, increasing mobil-
ity and exercise made possible by improved lung function 
might precipitate angina. The study also showed that more 
patients in the placebo groups discontinued treatment prema-
turely compared with the two tiotropium treatment groups. 
The discontinued patients had more severe lung disease 
at baseline than completers; this could have resulted in an 
over-estimation of treatment effects; however, low baseline 
FEV1 values were observed for discontinued patients across 
all treatment groups.
Fatal events occurred in 2.4% (Tio R5), 2.7% (Tio R10), 
and 1.6% (placebo) of patients; however, these differences 
were not significant. It was not possible to retrieve the causes 
of death in prematurely discontinued patients as these data 
were not collected for all patients during the retrospective 
study of vital status. Such studies are time-consuming and 
yield data of variable quality.
In the current study, the mortality (0.77%) in the placebo 
group during treatment plus the 30-day observation period 
is unusually low in comparison with placebo arms in 
selected published trials (44- to 52-week duration, 250 
COPD patients of similar severity per study arm): 1.57%,26 
1.95%,27 2.66%.28 The mortality in the Tio R5 group of 
1.79% is among the lowest in the range of active treat-
ment arms in these trials: 1.58% (roflumilast),28 1.63% 
(fluticasone-salmeterol),29 1.90% (salmeterol),26 1.97% 
(budesonide–formoterol),27 2.18% (salmeterol),29 2.33 
(budesonide),27 5.10% (formoterol).27 Differential discontinu-
ation of the most severe patients may bias against effective 
therapies, which could, in part, explain these findings. In the 
Inhaled Steroids in Obstructive Lung Disease (ISOLDE) 
study, withdrawal due to respiratory symptoms and rapid 
decline in health status were more common in placebo-treated 
patients than those on active treatment.30 Unfortunately, the 
positive impact of patients’ treatment being intensified after 
withdrawing from the study cannot be determined.
It is also difficult to interpret the differences in mortal-
ity rates observed in different studies. A recent publication 
by Hilleman et al,31 analyzing adverse outcomes associated 
with long-term anticholinergic use in such major trials as 
Investigating New Standards for Prophylaxis In Reduction of 
Exacerbations (INSPIRE),32 Understanding Potential Long-
term Impacts on Function with Tiotropium (UPLIFT®),33 
and the Lung Health Study (LHS),34 draws attention to the 
wide variation in reported rates of serious adverse events. 
Kesten et al35 has drawn attention to the considerably higher 
incidence rate of fatal events when study drug (tiotropium 
administered via a Handihaler®) is discontinued at the end 
of the trial period, compared with the time on-treatment 
(23.0 vs 1.9 per 100 patient-years, respectively), which 
may account for some of the reported differences between 
studies.35 These reports and our study highlight the need for 
prospective standardized reporting of causes of deaths both 
during and following discontinuation of study drug in future 
COPD trials.
In summary, these data show that tiotropium (5 and 
10 µg), delivered via Respimat® SMI, is effective and well 
tolerated in the long-term treatment of COPD, and the find-
ings are consistent with those observed with tiotropium 18 µg 
HandiHaler®.16–18 Given that there was no advantage of 10 µg 
tiotropium over the 5 µg dose for the four co-primary efficacy 
endpoints, the lower dose (tiotropium 5 µg) appears to be 
optimal when Respimat® SMI is the preferred device. The 
current study was based on requirements for international 
registration of the Respimat® doses; however, phase IV trials 
are planned to compare long-term administration of tiotro-
pium delivered by Respimat® and HandiHaler®.International Journal of COPD 2010:5 207
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